ClinicalTrials.gg
CompletedNCT03341312Updated Jun 9, 2020Results posted

A Comparative Study of LY900014 With Insulin Lispro (Humalog) in Participants With Type 2 Diabetes Mellitus (T2DM)

A Phase 1 interventional study of LY900014 and Insulin Lispro in Diabetes Mellitus, Type 2, sponsored by Eli Lilly and Company. Completed at 2 sites in Germany. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-06-09.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 — none open to participants now, none under way, none of them phase 3. Insulin Lispro · Diabetes Mellitus, Type 2.

Enrollment
28th of 36
36 · median 127
Started
2017
with 4 others
Phase 1
7 of 36
none open now
Registered
28th of 36
by date
Lead sponsor
26 of 36
Eli Lilly and Company

Among the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2, this one is the 28th largest by enrollment, is one of 5 that started in 2017, is one of 7 in phase 1, and was the 28th registered.

Diabetes Mellitus, Type 2

10,382 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

None of the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 is open now. The open studies under Diabetes Mellitus, Type 2, anywhere →

About Insulin Lispro

Insulin Lispro: first FDA approval 1996 (HUMALOG KWIKPEN), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 36 studies testing Insulin Lispro in Diabetes Mellitus, Type 2 as a file.
02

Study summary

The purpose of this study is to evaluate a new formulation of insulin lispro, LY900014, which is a drug that lowers blood sugar. The study will look at how the body processes LY900014, and the effect of LY900014 on blood sugar levels following a standard meal. For each participant, the study will consist of 4 periods and will last approximately 12 weeks from screening to final study follow up.

03

Conditions studied

  • Diabetes Mellitus, Type 2
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a (BMI) of 18.5 kilogram per meter square (kg/m²) to 40.0 kg/m²
  • Have a (HbA1c) less than or equal to (≤)9.0%
  • Have a fasting C-peptide ≤1.0 nanomole per liter (nmol/L)
  • Are on stable prandial insulin and basal insulin (neutral protamine Hagedorn [NPH] insulin, insulin glargine or insulin detemir) with or without a stable dose of metformin for at least 3 months before screening

Exclusion criteria

Exclusion Criteria:

  • Are currently enrolled, or have participated within the last 30 days, in a clinical trial or any other type of medical research
  • Have or used to have health problems that, in the opinion of the doctor, could make it unsafe to participate in the study
  • Have donated blood of more than 450 millilitre (mL) or more in the last 3 months or provided any blood donation within the last month before screening
  • Any significant changes in insulin regimen and/or unstable blood glucose control within the past 3 months prior to screening as assessed by the investigator
  • Are treated with a CSII (insulin pump)
  • Require daily insulin treatment greater than (>)1.2 units per kilogram per body weight (U/kg/body weight)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    LY900014 Before Meal

    Individualized dose of LY900014 administered subcutaneously (SC) immediately before meal in one of four study periods.

    Biological: LY900014

  • Experimental
    LY900014 After Meal

    Individualized dose of LY900014 administered SC 20 minutes after start of meal in one of four study periods.

    Biological: LY900014

  • Active comparator
    Insulin Lispro (Humalog) Before Meal

    Individualized dose of insulin lispro administered SC immediately before meal in one of four study periods.

    Biological: Insulin Lispro

  • Active comparator
    Insulin Lispro (Humalog) After Meal

    Individualized dose of insulin lispro administered SC 20 minutes after start of meal in one of four study periods.

    Biological: Insulin Lispro

Interventions

  • BiologicalLY900014

    Administered SC

    Also known as: Ultra-Rapid Lispro

  • BiologicalInsulin Lispro

    Administered SC

    Also known as: LY275585, Humalog

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr)

    PK: Insulin Lispro AUC for Each Treatment Arm. PK: Insulin Lispro AUC for Each Treatment Arm. LY900014 before and after meal and insulin lispro (Humalog) before and after meal were pooled by treatment to evaluate the overall PK of LY900014 and insulin lispro (Humalog) per protocol .

    Time frame: Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes (7 hours) postdose

Secondary outcomes

  1. Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm

    GD: Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm

    Time frame: -30, -15, 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240, and 300 minutes post-meal

07

Results

Posted Jun 9, 2020

Participant flow

Period 1
Participant flow — Period 1
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started91098
Received at least one dose of study drug91098
Completed9998
Not completed0100
Withdrew: Withdrawal by subject0100
Period 2
Participant flow — Period 2
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started9998
Completed9998
Not completed0000
Period 3
Participant flow — Period 3
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started9998
Completed9998
Not completed0000
Period 4
Participant flow — Period 4
MilestoneCohort 1Cohort 2Cohort 3Cohort 4
Started9998
Completed9998
Not completed0000

Outcome measures

PrimaryPharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr)

PK: Insulin Lispro AUC for Each Treatment Arm. PK: Insulin Lispro AUC for Each Treatment Arm. LY900014 before and after meal and insulin lispro (Humalog) before and after meal were pooled by treatment to evaluate the overall PK of LY900014 and insulin lispro (Humalog) per protocol .

Time frame:
Predose, 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 90, 120, 150, 180, 240, 300, 360, and 420 minutes (7 hours) postdose
Reported as:
Geometric mean · picomol times hour per Liter
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr)
picomol times hour per LiterLY900014Insulin Lispro (Humalog)
Pharmacokinetics (PK): Insulin Lispro Area Under the Concentration Curve Zero to Seven Hours (AUC0-7hr)1320 ± 631240 ± 68
SecondaryGlucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm

GD: Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm

Time frame:
-30, -15, 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 135, 150, 165, 180, 195, 210, 225, 240, and 300 minutes post-meal
Reported as:
Mean · milligrams times hour per deciliter
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm
milligrams times hour per deciliterLY900014 Before MealLY900014 After MealInsulin Lispro (Humalog) Before MealInsulin Lispro (Humalog) After Meal
Glucodynamics (GD): Area Under the Baseline Subtracted Glucose Concentration Curve (BGΔAUC) for Each Treatment Arm97.8 ± 155112 ± 139131 ± 155146 ± 150
Statistical analysis
  • LY900014 Before Meal vs Insulin Lispro (Humalog) Before Meal · Ratio of ls means: 0.75 · 95% CI 0.42 to 1.16
  • LY900014 After Meal vs Insulin Lispro (Humalog) After Meal · Ratio of ls means: 0.74 · 95% CI 0.49 to 1.01

Adverse events

Collected over 4 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY900014 Before Meal0/35 (0%)0/35 (0%)1/35 (2.9%)
LY900014 After Meal0/36 (0%)0/36 (0%)2/36 (5.6%)
Insulin Lispro (Humalog) Before Meal0/35 (0%)0/35 (0%)1/35 (2.9%)
Insulin Lispro (Humalog) After Meal0/35 (0%)0/35 (0%)0/35 (0%)
Most frequent other events
Most frequent other events
EventLY900014 Before MealLY900014 After MealInsulin Lispro (Humalog) Before MealInsulin Lispro (Humalog) After Meal
Injection site reactionGeneral disorders1/352/361/350/35

Baseline characteristics

All randomized participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(years)Overall Study
Mean60.8 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Overall Study
Female5
Male31
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Overall Study
Hispanic or Latino0
Not Hispanic or Latino36
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Overall Study
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White36
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)Overall Study
Germany36
Duration of T2DM
Duration of T2DM(years)Overall Study
Mean16.704 ± 8.957
08

Study locations

2 sites
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Mainz, Germany
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST) or speak with your personal physician.
    Neuss, Germany
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2017 to primary completion in Mar 2018, 4 months.

Results were first posted in Jun 2020, 2 years 2 months after primary completion.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 4 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2017
First posted
Nov 14, 2017
StartActual
Nov 13, 2017
Primary completionActual
Mar 31, 2018
CompletionActual
Mar 31, 2018
Results first posted
Jun 9, 2020
Last update
Jun 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03341312
Responsible party
Sponsor
First posted
Nov 14, 2017
Start date
Nov 13, 2017
Primary completion
Mar 31, 2018
Completion
Mar 31, 2018
Results posted
Jun 9, 2020
Last update
Jun 9, 2020

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Lispro

Start the discussion